

7 December 2010

## Completion of \$2.4 Million Rights Issue

Antisense Therapeutics Limited (ASX:ANP) is pleased to announce the successful completion of the Company's 1:2 renounceable Rights Issue.

The number of new ordinary shares subscribed for by eligible shareholders and new applicants was 126,256,962 with 1:5 free attaching options. Subject to the terms of the Underwriting Agreement, the remaining 169,907,174 shares will be taken up by the Underwriter and Lead Manager to the Issue, Patersons Securities Limited, for a total raising of approximately \$2.4 million before issue costs.

The net proceeds will be applied to moving ATL1103 (for growth and sight disorders) into clinical development and to implement the Company's strategy to realise value from its other project assets in the form of licensing or partnering agreements.

Antisense Therapeutics wishes to thank all shareholders who participated in this Issue for their continued support of the Company and looks forward to providing updates in relation to the above development and licensing opportunities.

Allotment of securities is scheduled to occur on 9<sup>th</sup> December 2010.

The holding statements for shares and new options are expected to be dispatched on 10<sup>th</sup> December 2010.

**Antisense Therapeutics Limited** (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise antisense pharmaceuticals for large unmet markets. ANP has two drugs in development and two drugs in pre-clinical research. ATL1102 (injection) has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of MRI lesions in patients with multiple sclerosis. ATL1103 is a second-generation antisense drug designed to lower blood IGF-I levels and is entering the clinical stage of development as a potential treatment for growth and vision disorders. ATL1102 (inhaled) is at the pre-clinical research stage as a potential treatment for asthma. ATL1101 is a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for prostate cancer.

**Contact Information:** Website: [www.antisense.com.au](http://www.antisense.com.au)  
Managing Director: Mark Diamond +61 3 9827 8999  
Investor Relations: Simon Watkin +61 (0) 413 153272